Long noncoding RNA FEZF1-AS1 in human cancers

Clin Chim Acta. 2019 Oct:497:20-26. doi: 10.1016/j.cca.2019.07.004. Epub 2019 Jul 2.

Abstract

Long noncoding RNAs (lncRNAs) have been shown to play key roles in various human tumors. Ectopic expression of the lncRNA FEZ finger zinc 1 antisense 1 (FEZF1-AS1) have been reported in different cancers, including colorectal cancer, gastric neoplasia, hepatocellular carcinoma and so on. Summarizing all literature correlated with FEZF1-AS1, it is obvious that FEZF1-AS1 is mainly involved in tumorigenesis and progression through competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA) and recruiting mechanism. Moreover, the aberrant expression of FEZF1-AS1 is related to clinical features of patients with cancers, and regulates cellular proliferation, anti-apoptosis, invasion and metastasis through diverse underlying mechanisms. The role of FEZF1-AS1 in carcinogenesis and progression suggests that it may be a potential diagnostic biomarker or a novel therapeutic target for cancers.

Keywords: Biomarker; Cancer; FEZF1-AS1; Long noncoding RNA.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular / genetics*
  • Colorectal Neoplasms / genetics*
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Liver Neoplasms / genetics*
  • RNA, Antisense / genetics*
  • RNA, Long Noncoding / genetics*
  • Repressor Proteins / genetics*
  • Stomach Neoplasms / genetics*

Substances

  • FEZF1 protein, human
  • RNA, Antisense
  • RNA, Long Noncoding
  • Repressor Proteins